More recently, the use of EGFR and ALK inhibitors in lung cancer patients whose tumours harbour EGFR mutations and EML4-ALK rearrangements, respectively, as well as BRAF inhibitors in melanoma has resulted in significantly improved response rates compared to conventional therapies in those subsets of patients [5,6,9]. This evidence concerns the gene EML4 and lung carcinoma.